CN106619491A - 一种药物缓释水凝胶及其制备方法 - Google Patents
一种药物缓释水凝胶及其制备方法 Download PDFInfo
- Publication number
- CN106619491A CN106619491A CN201710059197.XA CN201710059197A CN106619491A CN 106619491 A CN106619491 A CN 106619491A CN 201710059197 A CN201710059197 A CN 201710059197A CN 106619491 A CN106619491 A CN 106619491A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- slow release
- medicament slow
- release hydrogel
- tartaric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000017 hydrogel Substances 0.000 title claims abstract description 64
- 229940079593 drug Drugs 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000013268 sustained release Methods 0.000 title abstract description 6
- 239000012730 sustained-release form Substances 0.000 title abstract description 6
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 26
- 235000002906 tartaric acid Nutrition 0.000 claims description 26
- 239000011975 tartaric acid Substances 0.000 claims description 26
- 239000000178 monomer Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000004806 packaging method and process Methods 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 230000000149 penetrating effect Effects 0.000 claims description 13
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical group O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 8
- 230000005251 gamma ray Effects 0.000 claims description 6
- 229960000905 indomethacin Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical group CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- 238000000748 compression moulding Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 1
- -1 polyethylene pyrrole Pyrrolidone Polymers 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 5
- 239000011159 matrix material Substances 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 abstract 2
- 239000004925 Acrylic resin Substances 0.000 abstract 2
- YADMSCZEQAZFKU-UHFFFAOYSA-N C(CC)S(=O)(=O)OCCCCCCCCCCCCCC.[Na].C1(\C=C/C(=O)O1)=O Chemical compound C(CC)S(=O)(=O)OCCCCCCCCCCCCCC.[Na].C1(\C=C/C(=O)O1)=O YADMSCZEQAZFKU-UHFFFAOYSA-N 0.000 abstract 2
- 239000003961 penetration enhancing agent Substances 0.000 abstract 2
- 229940047670 sodium acrylate Drugs 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 description 5
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MQVMJSWYKLYFIG-UHFFFAOYSA-N propane-1-sulfonic acid;sodium Chemical compound [Na].CCCS(O)(=O)=O MQVMJSWYKLYFIG-UHFFFAOYSA-N 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F265/00—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00
- C08F265/02—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00 on to polymers of acids, salts or anhydrides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开一种药物缓释水凝胶，包括如下重量百分比的原料：0.1～1％的药物分子、1～5％的促渗剂，0.2～2％的马来酸酐十四醇基丙磺酸钠、6～45％的溶剂、1～15％的丙烯酸钠树脂、0.01～1％的交联剂、1～15％的增粘剂、0.01～0.5％的催化剂以及余量水。本发明还公开了一种药物缓释水凝胶的制备方法，先将马来酸酐十四醇基丙磺酸钠与药物分子、溶剂和促渗剂共混，生成有表面活性的单体包裹药物后，将该单体包裹药物在由丙烯酸钠树脂、交联剂、增粘剂以及催化剂的水溶液构成的水凝胶基质中进行辐照聚合，即得该药物缓释水凝胶产品，该药物缓释水凝胶的缓释效果好，药物释放的稳定性有所提高。
Description
技术领域
本发明涉及高分子技术领域及药物缓释型技术领域，具体涉及的是一种药物缓释水凝胶及其制备方法。
背景技术
水凝胶是一类以水溶性高分子聚合物为基质骨架材料的交联聚合物，具有载药量大，保湿性强，与皮肤的相容性好，耐老化等特点，因此水凝胶可广泛应用在组织修复、人造器官、药物缓释及传感器等诸多领域。常用作药物缓释载体的水凝胶贴可以反复揭贴、随时终止给药；且保证剂量准确，血药浓度平衡无峰谷现象，可减少毒副作用；在工业生产中无有机溶媒污染，符合环保要求，从而成为当代药剂学研究的热门之一。
水凝胶的药物释放过程是一个动力学和热力学的复合过程，为了让水凝胶的释放作用更加稳定，通常加入粉料来延长产品的扩散通道，稳定药物释放的过程，例如日本药店贩售的水凝胶药剂就有规定加入高岭土用于稳定药物释放的过程。但是，现有的水凝胶仍存在缓释效果差、不稳定等问题，使得有效成分不能发挥应有的药效，因此，水凝胶的药物释放的稳定性问题仍有进一步探讨的空间。
发明内容
本发明的目的在于提供一种药物缓释水凝胶及其制备方法，制备的水凝胶缓释效果好，药物释放的稳定性有所提高。
为了达成上述目的，本发明的解决方案是：
一种药物缓释水凝胶，包括如下重量百分比的原料：
所述促渗剂为月桂氮酮或者二甲亚砜，所述交联剂为甘羟铝，所述增粘剂为聚乙烯吡咯烷酮，所述催化剂为酒石酸。
所述药物分子为吲哚美辛或者布洛芬。
所述丙烯酸钠树脂由日本昭和公司购买得到。
所述溶剂为乙醇和丙三醇的混合物，所述乙醇的重量百分用量为1～5％，所述丙三醇的重量百分用量为5～40％。
该药物缓释水凝胶的制备方法，包括以下步骤：
(1)将0.2～2％的马来酸酐十四醇基丙磺酸钠、6～45％的溶剂、1～5％的促渗剂以及0.1～1％的药物分子混合均匀，形成单体包裹药物溶液；
(2)将0.01～0.5％的催化剂酒石酸溶于水中制备成酒石酸水溶液；
(3)向步骤(1)得到的所述单体包裹药物溶液中依次加入1～15％的丙烯酸钠树脂、0.01～1％的交联剂甘羟铝、1～15％的增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将所述水凝胶前驱物模压成型，在60Coγ射线下辐照后取出，所述60Coγ射线的辐照量为0.5-8kGy，即得该药物缓释水凝胶产品；步骤(1)～(3)中各组分的用量总和为100％。
步骤(1)中，所述溶剂为乙醇和丙三醇的混合物，所述乙醇的重量百分用量为1～5％，所述丙三醇的重量百分用量为5～40％。
马来酸酐十四醇基丙磺酸钠是经典的无皂乳液聚合中的反应性高分子乳化单体【Acta Polymerica,1998,29(12):4508-4515】，具有良好的乳化能力，在本发明的技术方案中，将其作为自乳化单体，先与药物分子、溶剂和促渗剂共混，生成有表面活性的单体包裹药物后，将该单体包裹药物在由丙烯酸钠树脂、交联剂甘羟铝、增粘剂聚乙烯吡咯烷酮以及酒石酸水溶液构成的水凝胶基质中进行辐照聚合，通过辐照使得马来酸酐十四醇基丙磺酸钠交联形成胶束粒子，从而获得稳定的胶束粒子包裹的缓释药物水凝胶，由此提高药物释放的稳定性。
附图说明
图1为本发明实施例一中制备得到的药物缓释水凝胶(A)与市售水凝胶巴布贴(B)的缓释效果对比图。
具体实施方式
为了进一步解释本发明的技术方案，下面通过具体实施例来对本发明进行详细阐述。
一种药物缓释水凝胶，包括如下重量百分比的原料：
所述促渗剂为月桂氮酮或者二甲亚砜，所述交联剂为甘羟铝，所述增粘剂为聚乙烯吡咯烷酮，所述催化剂为酒石酸。
所述药物分子为吲哚美辛或者布洛芬。
所述丙烯酸钠树脂由日本昭和公司购买得到。
所述溶剂为乙醇和丙三醇的混合物，所述乙醇的重量百分用量为1～5％，所述丙三醇的重量百分用量为5～40％。
一种药物缓释水凝胶的制备方法，包括以下步骤：
(1)将0.2～2％的马来酸酐十四醇基丙磺酸钠、6～45％的溶剂、1～5％的促渗剂以及0.1～1％的药物分子混合均匀，形成单体包裹药物溶液；
(2)将0.01～0.5％的催化剂酒石酸溶于水中制备成酒石酸水溶液；
(3)向步骤(1)得到的所述单体包裹药物溶液中依次加入1～15％的丙烯酸钠树脂、0.01～1％的交联剂甘羟铝、1～15％的增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将所述水凝胶前驱物模压成型，在60Coγ射线下辐照后取出，所述60Coγ射线的辐照量为0.5-8kGy，即得该药物缓释水凝胶产品；步骤(1)～(3)中各组分的用量总和为100％。
实施例一
该药物缓释水凝胶的制备方法，包括以下步骤：
(1)按照配方比例，将0.5g马来酸酐十四醇基丙磺酸钠、3g乙醇、15g丙三醇、0.35g吲哚美辛以及2g促渗剂月桂氮酮混合均匀，形成单体包裹药物溶液；
(2)将0.1g催化剂酒石酸溶于64.03g水中制备成酒石酸水溶液；
(3)向步骤(1)得到的单体包裹药物溶液中依次加入10g丙烯酸钠树脂、0.02g交联剂甘羟铝、5g增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将水凝胶前驱物模压成片状，在60Coγ射线下辐照后取出，60Coγ射线的辐照量为4kGy，即得该药物缓释水凝胶产品。
为了更好地证明该药物缓释水凝胶的缓释效果，将该药物缓释水凝胶(A)与市售水凝胶巴布贴(B)进行了对比，两者的药物分子的含量相同，结果如图1所示，其中x轴为时间(h)，y轴为释放百分比(％)。结果表明：该药物缓释水凝胶产品的缓释效果和稳定性都较佳。
实施例二
该药物缓释水凝胶的制备方法，包括以下步骤：
(1)按照配方比例，将0.8g马来酸酐十四醇基丙磺酸钠、3g乙醇、20g丙三醇、0.5g吲哚美辛以及2.5g促渗剂月桂氮酮混合均匀，形成单体包裹药物溶液；
(2)将0.1g催化剂酒石酸溶于55.08g水中制备成酒石酸水溶液；
(3)向步骤(1)得到的单体包裹药物溶液中依次加入10g丙烯酸钠树脂、0.02g交联剂甘羟铝、8g增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将水凝胶前驱物模压成片状，在60Coγ射线下辐照后取出，60Coγ射线的辐照量为0.5kGy，即得该药物缓释水凝胶产品。
实施例三
该药物缓释水凝胶的制备方法，包括以下步骤：
(1)按照配方比例，将2g马来酸酐十四醇基丙磺酸钠、3g乙醇、10g丙三醇、0.5g吲哚美辛以及3g促渗剂二甲亚砜混合均匀，形成单体包裹药物溶液；
(2)将0.1g催化剂酒石酸溶于54.35g水中制备成酒石酸水溶液；
(3)向步骤(1)得到的单体包裹药物溶液中依次加入15g丙烯酸钠树脂、0.05g交联剂甘羟铝、12g增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将水凝胶前驱物模压成片状，在60Coγ射线下辐照后取出，60Coγ射线的辐照量为2kGy，即得该药物缓释水凝胶产品。
实施例四
该药物缓释水凝胶的制备方法，包括以下步骤：
(1)按照配方比例，将1.5g马来酸酐十四醇基丙磺酸钠、5g乙醇、20g丙三醇、0.5g布洛芬以及2g促渗剂月桂氮酮混合均匀，形成单体包裹药物溶液；
(2)将0.1g催化剂酒石酸溶于50.7g水中制备成酒石酸水溶液；
(3)向步骤(1)得到的单体包裹药物溶液中依次加入15g丙烯酸钠树脂、0.2g交联剂甘羟铝、5g增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将水凝胶前驱物模压成片状，在60Coγ射线下辐照后取出，60Coγ射线的辐照量为6kGy，即得该药物缓释水凝胶产品。
实施例五
该药物缓释水凝胶的制备方法，包括以下步骤：
(1)按照配方比例，将1g马来酸酐十四醇基丙磺酸钠、3g乙醇、15g丙三醇、0.5g吲哚美辛以及4g促渗剂二甲亚砜混合均匀，形成单体包裹药物溶液；
(2)将0.4g催化剂酒石酸溶于54.3g水中制备成酒石酸水溶液；
(3)向步骤(1)得到的单体包裹药物溶液中依次加入12g丙烯酸钠树脂、0.8g交联剂甘羟铝、9g增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将水凝胶前驱物模压成片状，在60Coγ射线下辐照后取出，60Coγ射线的辐照量为8kGy，即得该药物缓释水凝胶产品。
上述实施例和图式并非限定本发明的产品形态和式样，任何所属技术领域的普通技术人员对其所做的适当变化或修饰，皆应视为不脱离本发明的专利范畴。
Claims (5)
1.一种药物缓释水凝胶，其特征在于：包括如下重量百分比的原料：
所述促渗剂为月桂氮酮或者二甲亚砜，所述交联剂为甘羟铝，所述增粘剂为聚乙烯吡咯烷酮，所述催化剂为酒石酸。
2.根据权利要求1所述的一种药物缓释水凝胶，其特征在于：所述药物分子为吲哚美辛或者布洛芬。
3.根据权利要求1所述的一种药物缓释水凝胶，其特征在于：所述溶剂为乙醇和丙三醇的混合物，所述乙醇的重量百分用量为1～5％，所述丙三醇的重量百分用量为5～40％。
4.制备如权利要求1所述的一种药物缓释水凝胶的制备方法，其特征在于：包括以下步骤：
(1)将0.2～2％的马来酸酐十四醇基丙磺酸钠、6～45％的溶剂、1～5％的促渗剂以及0.1～1％的药物分子混合均匀，形成单体包裹药物溶液，所述促渗剂为月桂氮酮或者二甲亚砜；
(2)将0.01～0.5％的催化剂酒石酸溶于水中制备成酒石酸水溶液；
(3)向步骤(1)得到的所述单体包裹药物溶液中依次加入1～15％的丙烯酸钠树脂、0.01～1％的交联剂甘羟铝、1～15％的增粘剂聚乙烯吡咯烷酮以及步骤(2)得到的酒石酸水溶液，混合均匀，得到稠状的水凝胶前驱物；
(4)将所述水凝胶前驱物模压成型，在60Coγ射线下辐照后取出，所述60Coγ射线的辐照量为0.5-8kGy，即得该药物缓释水凝胶产品；步骤(1)～(3)中各组分的用量总和为100％。
5.根据权利要求4所述的一种药物缓释水凝胶的制备方法，其特征在于：步骤(1)中，所述溶剂为乙醇和丙三醇的混合物，所述乙醇的重量百分用量为1～5％，所述丙三醇的重量百分用量为5～40％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710059197.XA CN106619491B (zh) | 2017-01-24 | 2017-01-24 | 一种药物缓释水凝胶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710059197.XA CN106619491B (zh) | 2017-01-24 | 2017-01-24 | 一种药物缓释水凝胶及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106619491A true CN106619491A (zh) | 2017-05-10 |
| CN106619491B CN106619491B (zh) | 2019-04-30 |
Family
ID=58841377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710059197.XA Active CN106619491B (zh) | 2017-01-24 | 2017-01-24 | 一种药物缓释水凝胶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619491B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108403622A (zh) * | 2018-05-24 | 2018-08-17 | 杭州求是医学科技有限公司 | 一种水凝胶及应用该水凝胶制作降温贴的工艺 |
| CN113827579A (zh) * | 2021-11-03 | 2021-12-24 | 马鞍山师范高等专科学校 | 一种缓释凝胶药贴的制备方法及设备 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1449742A (zh) * | 2003-05-14 | 2003-10-22 | 沈阳药科大学 | 难溶性药物透皮吸收制剂及其制备工艺 |
| CN102757538A (zh) * | 2011-04-21 | 2012-10-31 | 中国科学院成都有机化学有限公司 | 一种智能型天然高分子-合成高分子共聚物微凝胶及其制备方法 |
| CN103201345A (zh) * | 2010-10-01 | 2013-07-10 | Ppg工业俄亥俄公司 | 使用包含自乳化的聚酯微凝胶的底漆的方法 |
| CN103408469A (zh) * | 2013-08-27 | 2013-11-27 | 华鼎鸿基采油技术服务（北京）有限公司 | 新型聚合物表面活性剂的制备方法及应用 |
| CN104603169A (zh) * | 2013-06-19 | 2015-05-06 | Lg化学株式会社 | 多层核壳结构的橡胶聚合物胶乳及其制备方法,以及含有它的丙烯腈-丁二烯-苯乙烯接枝共聚物 |
| CN105168163A (zh) * | 2015-09-23 | 2015-12-23 | 中国药科大学 | 难溶性药物口服缓释干乳片及其制备方法 |
| CN106084278A (zh) * | 2016-04-20 | 2016-11-09 | 陕西师范大学 | 一种半互穿网络纳米杂合水凝胶及其制备方法和应用 |
-
2017
- 2017-01-24 CN CN201710059197.XA patent/CN106619491B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1449742A (zh) * | 2003-05-14 | 2003-10-22 | 沈阳药科大学 | 难溶性药物透皮吸收制剂及其制备工艺 |
| CN103201345A (zh) * | 2010-10-01 | 2013-07-10 | Ppg工业俄亥俄公司 | 使用包含自乳化的聚酯微凝胶的底漆的方法 |
| CN102757538A (zh) * | 2011-04-21 | 2012-10-31 | 中国科学院成都有机化学有限公司 | 一种智能型天然高分子-合成高分子共聚物微凝胶及其制备方法 |
| CN104603169A (zh) * | 2013-06-19 | 2015-05-06 | Lg化学株式会社 | 多层核壳结构的橡胶聚合物胶乳及其制备方法,以及含有它的丙烯腈-丁二烯-苯乙烯接枝共聚物 |
| CN103408469A (zh) * | 2013-08-27 | 2013-11-27 | 华鼎鸿基采油技术服务（北京）有限公司 | 新型聚合物表面活性剂的制备方法及应用 |
| CN105168163A (zh) * | 2015-09-23 | 2015-12-23 | 中国药科大学 | 难溶性药物口服缓释干乳片及其制备方法 |
| CN106084278A (zh) * | 2016-04-20 | 2016-11-09 | 陕西师范大学 | 一种半互穿网络纳米杂合水凝胶及其制备方法和应用 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108403622A (zh) * | 2018-05-24 | 2018-08-17 | 杭州求是医学科技有限公司 | 一种水凝胶及应用该水凝胶制作降温贴的工艺 |
| CN113827579A (zh) * | 2021-11-03 | 2021-12-24 | 马鞍山师范高等专科学校 | 一种缓释凝胶药贴的制备方法及设备 |
| CN113827579B (zh) * | 2021-11-03 | 2023-12-05 | 马鞍山师范高等专科学校 | 一种缓释凝胶药贴的制备方法及设备 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106619491B (zh) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3000833B1 (en) | Micelles comprising a triblock copolymer and a therapeutic agent | |
| Wu et al. | Redox-responsive core-cross-linked mPEGylated starch micelles as nanocarriers for intracellular anticancer drug release | |
| CN104558421A (zh) | 一种具有pH/温度响应性的接枝纤维素药用分子制备方法 | |
| CN106619491A (zh) | 一种药物缓释水凝胶及其制备方法 | |
| Ahmed | Formulation and clinical investigation of optimized vinpocetine lyoplant-tabs: new strategy in development of buccal solid dosage form | |
| Dadou et al. | Elucidation of the controlled-release behavior of metoprolol succinate from directly compressed xanthan gum/chitosan polymers: Computational and experimental studies | |
| CN103520729B (zh) | 用于制备以淀粉为基质的硬胶囊的增韧成型助剂和用途 | |
| CN102895215A (zh) | 纤维素红藻多糖植物空心胶囊及其原料组合物和制备方法 | |
| Sabalingam et al. | A review on emerging applications of emulgel as topical drug delivery system | |
| CN106174440A (zh) | 一种多分子层可控营养物缓释纳米乳凝胶的制备方法 | |
| Mukherjee et al. | Studies on Span based Soy-bigels with HPMC | |
| Nandi et al. | Fabrication and evaluation of matrix type novel transdermal patch loaded with tramadol hydrochloride | |
| WO2017013682A1 (en) | Process of preparation of co-processed polymer and it's pharmaceutical application | |
| Gasztych et al. | Synthesis, evaluation and release studies of NIPA nanopolymers presumed for temperature-controlled drug delivery | |
| Navaneetha et al. | Formulation and in-vitro evaluation of capsaicin emulgel for topical delivery | |
| CN105218835A (zh) | 一种角蛋白基双敏感高分子凝胶的制备及作为药物载体的应用 | |
| Prusty et al. | Development and evaluation of matrix tablet by taking new chemicals combination of Chitosan and Eudragit-l 100 | |
| CN105342986A (zh) | 盐酸特比萘芬凝胶及其制备方法 | |
| CN103520730A (zh) | 一种可负载疏水性抗肿瘤药物的壳寡糖纳米粒 | |
| CN103536926A (zh) | 一种壳寡糖纳米粒的制备方法 | |
| CN103520115B (zh) | 盐酸维拉帕米缓释微球及其制备方法 | |
| CN112972385B (zh) | 一种消炎镇痛气雾剂及其制备方法 | |
| Soujith et al. | Terbinafine HCl Film-Forming Spray for the Treatment of Topical Fungal Infections | |
| Nandi et al. | Fabrication and Evaluation of Matrix Type Novel Transdermal Patch Loaded with Tramadol Hydrochloride Tramadol Hidroklorür Yüklü Matris Tipi Yeni Transdermal Yamanın İmalatı ve Değerlendirilmesi | |
| Sharma et al. | Polyethylene oxide-polypropylene oxide based block copolymers as nanovehicles for drug formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240322 Address after: 362000 1st floor, building D, factory building, 249 Keji Road, Huacheng community, Huada street, Fengze District, Quanzhou City, Fujian Province Patentee after: Fujian Longfeng Biotechnology Co.,Ltd. Country or region after: China Address before: 362000 1st floor, building D, Haixi electronic information industry breeding base, Keji Road, high tech Industrial Park, Fengze District, Quanzhou City, Fujian Province Patentee before: QUANZHOU YALIN NEW MATERIAL TECHNOLOGY CO.,LTD. Country or region before: China |